Treatment for severe tricuspid regurgitation using the Pivot Extend device

Early Feasibility Study (EFS) of the 'Pivot Extend' in Treatment for Tricuspid Regurgitation (SPACER Study)

This study is testing a new device to see if it can help people with severe tricuspid regurgitation who haven't improved with regular treatments.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 7 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Tau-MEDICAL Co., Ltd. (Industry-sponsored)
• Locations: 3 sites (Tbilisi, K'alak'i T'bilisi and 2 other locations)
• Trial ID: NCT06877520 on ClinicalTrials.gov

What this trial studies

This clinical trial evaluates the safety and efficacy of the Pivot Extend device for treating severe tricuspid regurgitation (TR) symptoms in patients who have not responded to standard medical therapy. Participants will undergo long-term implantation of the device, and the study will monitor for major adverse cardiovascular events (MACEs) as well as clinical outcomes related to the device's performance. The trial aims to provide insights into the procedural success and overall effectiveness of this innovative treatment approach.

Who should consider this trial

Good fit: Ideal candidates include adults over 18 with severe tricuspid regurgitation symptoms who have not responded to medical therapy.

Not a fit: Patients with blood clots or other vascular issues in the heart or lungs may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly improve the quality of life for patients suffering from severe tricuspid regurgitation.

How similar studies have performed: While this approach is innovative, similar studies have shown promise in treating other forms of heart valve disease, suggesting potential for success.

Eligibility criteria

Inclusion Criteria:

1. Adults 18 years of age or older at the time of screening
2. Those with symptoms despite medical therapy (OMT, diuretics/medications) for TR for at least 1 month at screening
3. Those who meet the criteria of severe (3+) or worse on the TR grade classification table on echocardiography performed at the screening visit
4. Those with clinical symptoms of New York Heart Association (NYHA) class 2 or worse
5. Those deemed suitable for percutaneous valve intervention by a Heart Team that includes at least one cardiologist, one cardiac surgeon and one anesthesiologist.
6. Those who have voluntarily decided to participate in this clinical trial and have provided written informed consent
7. Those who can understand and follow the investigator's instructions and are able to participate for the entire duration of the study

Exclusion Criteria:

1. Those with blood clots, emboli, masses, or growths in the vascular system of the heart or lungs on an echocardiogram and cardiac CT scan performed at the screening visit
2. Those with uncorrected blood clotting disorders based on hemanalysis performed at the screening visit
3. Those who are unable to use anticoagulant agents (NOAC ex.Xarelto)
4. Those who have had major bleeding (not including minor bleeding, such as a nosebleed that can be hemostasized) treated with anticoagulants prior to participation in this clinical trial
5. Those with severe anemia (hemoglobin ≦10g/dL) that requires hospitalization
6. Those who have an implanted device such as an implantable cardioverter defibrillator (ICD) or pacemaker prior to participation in this clinical trial
7. Those whose anatomy, in the opinion of the investigator, is not suitable for implantation of an investigational medical device based on echocardiogram and cardiac CT scan performed at the screening visit
8. Those who require surgery or interventional procedures (coronary artery bypass graft (CABG) or surgery for atrial septal defect (ASD)) based on an echocardiogram performed at the screening visit
9. Those with a platelet count of 80,000/uL or less based on hemanalysis performed at the screening visit
10. Patients with pulmonary arterial hypertension with a TR Vmax greater than 3.5 m/s on echocardiography performed at the screening visit or a pulmonary vascular resistance of more than 3 Wood Units on right heart catheterization
11. Those with a left ventricular ejection fraction (LVEF) of less than 50% on echocardiogram performed at the screening visit
12. Those who have had active gastrointestinal bleeding or a digestive procedure within 3 months prior to participation in this study (those with the potential for gastrointestinal bleeding)
13. Those with a history of cerebrovascular accident (CVA) or transient ischemic attacks (TIA) within 30 days prior to participation in this clinical trial
14. Those with a history of myocardial infarction (MI) within 30 days prior to participation in this study
15. Those with active endocarditis requiring antibiotic treatment
16. Those with malignancies with end-stage renal failure requiring hemodialysis and other chronic conditions who have a life expectancy of less than one year
17. Those with moderate or severe aortic, pulmonary artery, or mitral stenosis on echocardiogram performed at the screening visit
18. Those with moderate or worse mitral valve regurgitation or severe aortic valve regurgitation on the echocardiogram performed at the screening visit
19. Those with calcification of the tricuspid valve lobes affecting the procedure on an echocardiogram performed at the screening visit
20. Those who have participated in another clinical trial within 30 days prior to participation in this clinical trial
21. Pregnant or nursing women, or women planning to become pregnant during the clinical trial period
22. Women of childbearing potential who are not using a medically accepted birth control method
23. Those with a coexisting condition, which most likely limits the participant´s life expectancy to less than one year.
24. Those with a preexisting pulmonary valve prosthesis or RV to PA conduit.
25. Those with clinical findings other than the above that, in the opinion of the investigator, are medically inappropriate for this clinical trial

Where this trial is running

Tbilisi, K'alak'i T'bilisi and 2 other locations

• Israeli-Georgian Medical Research Clinic Healthycore — Tbilisi, K'alak'i T'bilisi, Georgia (Recruiting)
• Tbilisi Heart and Vascular Clinic — Tbilisi, K'alak'i T'bilisi, Georgia (Recruiting)
• Tbilisi Heart Center — Tbilisi, K'alak'i T'bilisi, Georgia (Recruiting)

Study contacts

• Study coordinator: Markus Reinthaler, MD, PhD

Conditions Tricuspid Regurgitation; Pivot Extend; TauMedical